Journal
ONCOLOGY LETTERS
Volume 16, Issue 1, Pages 157-166Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/ol.2018.8617
Keywords
chimeric antigen receptor; programmed death-ligand 1; NCI-H358; A549
Categories
Funding
- National High Technology Research and Development Program of China [2014AA022206]
Ask authors/readers for more resources
A chimeric antigen receptor (CAR) is a type of fusion protein that comprises an antigen-recognition domain and signaling domains. In the present study, a programmed death-ligand 1 (PD-L1)-specific CAR, comprised of a single-chain variable fragment (scFv) derived from a monoclonal antibody, co-stimulatory domains of cluster of differentiation (CD) 28 and 4-1BB and a T-cell-activation domain derived from CD3 zeta, was designed. The construction was cloned and packaged into the lentiviral vector pLVX. Flow cytometry confirmed that peripheral blood mononuclear cells were efficiently transduced and that the CAR was successfully expressed on T cells. The cytotoxicity of transduced T cells was detected using PD-Ll-positive NCI-H358 bronchioalveolar carcinoma cells and A549 lung adenocarcinoma cells (with a low expression of PD-L1, only in the A549 cells). The results demonstrated mild cytotoxicity at an effector-to-target ratio of 10:1. An ELISA revealed a significant increase in the level of interferon-y released from T cells transduced with scl: v-2813z when the cells were co-cultured with PD-L1-positive NCI-11358 cells, while interkeukin-2 and tumor necrosis factor-a levels remained unchanged. These data indicated a potential method for the treatment of solid tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available